WO2020212911A3 - Combination therapies comprising daratumumab, bortezomib, thalidomide and dexamethasone and their uses - Google Patents

Combination therapies comprising daratumumab, bortezomib, thalidomide and dexamethasone and their uses Download PDF

Info

Publication number
WO2020212911A3
WO2020212911A3 PCT/IB2020/053621 IB2020053621W WO2020212911A3 WO 2020212911 A3 WO2020212911 A3 WO 2020212911A3 IB 2020053621 W IB2020053621 W IB 2020053621W WO 2020212911 A3 WO2020212911 A3 WO 2020212911A3
Authority
WO
WIPO (PCT)
Prior art keywords
daratumumab
bortezomib
thalidomide
dexamethasone
combination therapies
Prior art date
Application number
PCT/IB2020/053621
Other languages
French (fr)
Other versions
WO2020212911A2 (en
Inventor
Xiangyang Liu
Jordan SCHECTER
Original Assignee
Janssen Biotech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech, Inc. filed Critical Janssen Biotech, Inc.
Publication of WO2020212911A2 publication Critical patent/WO2020212911A2/en
Publication of WO2020212911A3 publication Critical patent/WO2020212911A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed herein are combination therapies comprising daratumumab, bortezomib, thalidomide and dexamethasone and their uses.
PCT/IB2020/053621 2019-04-19 2020-04-16 Combination therapies comprising daratumumab, bortezomib, thalidomide and dexamethasone and their uses WO2020212911A2 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201962836445P 2019-04-19 2019-04-19
US201962836492P 2019-04-19 2019-04-19
US201962836408P 2019-04-19 2019-04-19
US201962836361P 2019-04-19 2019-04-19
US62/836,408 2019-04-19
US62/836,361 2019-04-19
US62/836,445 2019-04-19
US62/836,492 2019-04-19

Publications (2)

Publication Number Publication Date
WO2020212911A2 WO2020212911A2 (en) 2020-10-22
WO2020212911A3 true WO2020212911A3 (en) 2021-05-14

Family

ID=72837774

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2020/053621 WO2020212911A2 (en) 2019-04-19 2020-04-16 Combination therapies comprising daratumumab, bortezomib, thalidomide and dexamethasone and their uses

Country Status (1)

Country Link
WO (1) WO2020212911A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170121414A1 (en) * 2015-11-03 2017-05-04 Janssen Biotech, Inc. Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses
EP3318642A1 (en) * 2016-11-02 2018-05-09 Centre National De La Recherche Scientifique Method for the in vitro prognosis of individuals having multiple myeloma and method for the treatment thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170121414A1 (en) * 2015-11-03 2017-05-04 Janssen Biotech, Inc. Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses
EP3318642A1 (en) * 2016-11-02 2018-05-09 Centre National De La Recherche Scientifique Method for the in vitro prognosis of individuals having multiple myeloma and method for the treatment thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CARVALHO, J, DARZALEX ADD-ON INCREASES COMPLETE RESPONSES AFTER STEM CELL TRANSPLANT, PHASE 3 MYELOMA TRIAL SHOWS, 24 October 2018 (2018-10-24), pages 1 - 2, XP055821443, Retrieved from the Internet <URL:https://myelomaresearchnews.com/2018/10/24/phase-3-myeloma-trial-shows-positive-results-darzalex-chemo-combo> [retrieved on 20210216] *

Also Published As

Publication number Publication date
WO2020212911A2 (en) 2020-10-22

Similar Documents

Publication Publication Date Title
MX2022010168A (en) Calpain modulators and therapeutic uses thereof.
EP4268892A3 (en) Matrix bound nanovesicles and their use
WO2018109170A3 (en) Il-11ra antibodies
EP3873991A4 (en) Foam compositions, foam matrices and methods
JOP20170055B1 (en) Composition for syrup containing allulose and food comprising the composition
WO2018109174A3 (en) Il-11 antibodies
WO2019183359A8 (en) Methods and compositions for molecular authentication
WO2016138091A3 (en) Selection methods for genetically-modified t cells
USD760837S1 (en) Teaching aid
EP4428234A3 (en) Direct-to-library methods, systems, and compositions
EP3874992A4 (en) Dissembleable chair base, and chair
WO2017155906A8 (en) Long lasting cosmetic compositions
EP3880704A4 (en) Regenerative abscopal effects
EP3911355A4 (en) Recombinant lubricins, and compositions and methods for using the same
GB201901099D0 (en) Methods, uses and compositions
GB202017595D0 (en) Compositions, and methods and uses relating thereto
EP4041274A4 (en) Ws-635 uses thereof in medicine
AU2019204711A1 (en) Securely performing cryptographic operations
EP3586264A4 (en) Securely performing cryptographic operations
EP3876631A4 (en) Distributed unit, central unit, and methods therefor
WO2020068196A3 (en) Proteins that inhibit cas12a (cpf1), a crispr-cas nuclease
EP4295903A3 (en) Compositions and methods for treating farber disease
WO2016115283A3 (en) Reagents and methods for whitening teeth
AU2018263385A1 (en) Protective articles and methods thereof
USD817514S1 (en) Service station

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20790976

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20790976

Country of ref document: EP

Kind code of ref document: A2